Alpha Cognition (NASDAQ:ACOG – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.03), Zacks reports.
Alpha Cognition Trading Down 8.5 %
Shares of ACOG opened at $5.06 on Tuesday. Alpha Cognition has a fifty-two week low of $4.66 and a fifty-two week high of $7.00. The business has a 50-day simple moving average of $5.83. The stock has a market capitalization of $81.06 million, a PE ratio of -1.98 and a beta of 2.50.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ACOG. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Alpha Cognition in a research note on Monday. Raymond James raised Alpha Cognition to a “moderate buy” rating in a research report on Tuesday, March 25th.
Alpha Cognition Company Profile
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Health Care Stocks Explained: Why You Might Want to Invest
- Amprius Market Gets Amped Up on Growth Outlook
- What Are Trending Stocks? Trending Stocks Explained
- ETFs With the Best Returns of 2025: Gold and Silver Miners on Top
- Want to Profit on the Downtrend? Downtrends, Explained.
- Paychex and Cintas Show Surprising Labor Market Resilience
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
